These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15781657)

  • 1. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
    Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
    Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
    Christensen C; Guldberg P
    Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
    Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
    Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
    Chen J; Shen Q; Labow M; Gaither LA
    Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
    Cui Y; Guadagno TM
    Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-RAF: A contributor to the melanoma phenotype.
    Heath EM; Kaufman KL; Christopherson RI
    Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.